idazoxan
Idazoxan (INN) is a drug which is used in scientific research. It acts as both a selective α2-adrenergic receptor antagonist, and an antagonist for the imidazoline receptor. Idazoxan has been under investigation as an antidepressant, but it did not reach the market as such. More recently, it is under investigation as an adjunctive treatment in schizophrenia. Due to its α2 receptor antagonism, it is capable of enhancing therapeutic effects of antipsychotics, possibly by enhancing dopamine neurotransmission in the prefrontal cortex of the brain, a brain area thought to be involved in the pathogenesis of schizophrenia. — Wikipedia
Clinical trial activity
4 trials · 4 clinical orgs · 0 marketing orgs
Earliest trial started Feb 19, 2006 (NCT00294944)
Timeline
Indications
Mechanism of action
- Adrenergic receptor alpha-2ANTAGONIST
Adrenergic receptor alpha-2 antagonist
- Alpha-2a adrenergic receptorINHIBITOR
ADRA2A inhibitor
Chemistry & pharmacology
SMILES
c1ccc2c(c1)OCC(C1=NCCN1)O2- Mol. weight
- 204.23 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Racemic Mixture
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaIdazoxan ↗
- ChEMBLCHEMBL10316 ↗
Also known as
- idazoxan
- idazoxan
- idazoxan
- idazoxan
- rx-781094
- rx-781094
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05727189 | Phase 1 | Feb 14, 2023 | Terran Biosciences Australia Pty Ltd |
| NCT02874820 | Early Phase 1 (Phase 1) | Jul 1, 2016 | GlaxoSmithKline, University of London |
| NCT02323217 | Early Phase 1 (Phase 1) | Jan 1, 2015 | GlaxoSmithKline, University of London |
| NCT00294944 | Phase 3 | Feb 19, 2006 | Tel Aviv University |
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| GlaxoSmithKline | For profit | 2 | 0 | 1 | 2015 |
| University of London | Academic/Hospital | 2 | 2 | 1 | 2015 |
| Tel Aviv University | Academic/Hospital | 1 | 1 | 1 | 2006 |
| Terran Biosciences Australia Pty Ltd | For profit | 1 | 1 | 1 | 2023 |